Institution Directory

Clinical trials at Children's Hospital of Philadelphia

Sites in Philadelphia, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 12:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

600

Shown on this page

Current sort

Live official records

Conditions: Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Interventions: ECMO support, PROSpect protocolized therapies; Device · Other
Lead sponsor: University of Michigan; Other
Eligibility: 14 Days to 20 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more

Conditions: Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma, Malignant Solid Neoplasm, Poorly Differentiated Chordoma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Chordoma, Recurrent Epithelioid Sarcoma, Recurrent Kidney Medullary Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Rhabdoid Tumor, Refractory Atypical Teratoid/Rhabdoid Tumor, Refractory Chordoma, Refractory Epithelioid Sarcoma, Refractory Kidney Medullary Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Rhabdoid Tumor, Rhabdoid Tumor
Interventions: Atezolizumab, Biospecimen Collection, Computed Tomography, Echocardiography Test, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography, Tiragolumab, X-Ray Imaging; Biological · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 35
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 30 more

Conditions: Central Nervous System Carcinoma
Interventions: Biospecimen Collection, Cognitive Assessment, Magnetic Resonance Imaging, Memantine Hydrochloride, Placebo Administration, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 4 Years to 17 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 137
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 110 more

Conditions: Cystic Fibrosis (CF)
Interventions: As-needed hypertonic saline (HS), Twice daily hypertonic saline (HS), As-needed dornase alfa (DA), Daily dornase alfa (DA); Other
Lead sponsor: Nicole Hamblett; Other
Eligibility: 3 Years to 16 Years
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 36
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 32 more

Conditions: Short Gut Syndrome
Interventions: Green bean puree; Dietary Supplement
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 4 Months to 18 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma, Glioblastoma, Malignant Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma
Interventions: Biospecimen Collection, Dabrafenib Mesylate, Lumbar Puncture, Magnetic Resonance Imaging, Radiation Therapy, Trametinib Dimethyl Sulfoxide; Procedure · Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 25 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 130
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 106 more

Conditions: Suicide, Attempted, Suicide Ideation, Suicide, Suicide Prevention
Interventions: Stanley Brown Safety Planning Intervention and Follow-up Contacts (SPI+), Interpersonal Psychotherapy for Adolescents Ultra Short Crisis Intervention (IPT-A SCI); Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 12 Years to 24 Years
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: St. Petersburg, Florida • Baltimore, Maryland • New York, New York + 2 more

Conditions: Cystic Fibrosis
Interventions: Ivacaftor or elexacaftor/tezacaftor/ivacaftor; Drug
Lead sponsor: Sonya Heltshe; Other
Eligibility: Up to 10 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 35
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 31 more

Conditions: Acute Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Mixed Lineage Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma, Juvenile Myelomonocytic Leukemia
Interventions: CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 25 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Duchenne Muscular Dystrophy
Interventions: SGT-003; Genetic
Lead sponsor: Solid Biosciences Inc.; Industry
Eligibility: 0 Years to 17 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 12
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 9 more

Conditions: Dysfunction of Eustachian Tube
Interventions: Not listed
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: Up to 18 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 9
States / cities: Palo Alto, California • Boston, Massachusetts • West Bloomfield, Michigan + 6 more

Conditions: T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Interventions: Allogeneic anti-CD7 CAR-T cells (BEAM-201); Biological
Lead sponsor: Stephan Grupp MD PhD; Other
Eligibility: 0 Years to 29 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

About this Children's Hospital of Philadelphia institution page

What this page lists: ClinicalTrials.gov records that list Children's Hospital of Philadelphia in Philadelphia, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Children's Hospital of Philadelphia

Filter and sort this campus

Live official records

ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor

Rethinking Early Airway Clearence Therapies

Fiber Food Introduction in Pediatric Short Bowel Syndrome

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

Preventing Suicidal Behavior With Diverse High-Risk Youth in Acute Care Settings

Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

AERA Pediatrics Registry

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

About this Children's Hospital of Philadelphia institution page